Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), announced a share buyback plan, indicating confidence in its financial position and future prospects [1] Group 1 - The company will repurchase 400,000 shares [1] - The total expenditure for the buyback is HKD 5.1349 million [1] - The buyback is scheduled for October 17, 2025 [1]

FF305 B. 贖回/購回股份 (擬註銷但截至期終結存日期尚未註銷) (註5及6) 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年10月17日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 ...

Summary of Key Points Core Viewpoint - A number of companies, including Xiaomi Group and Kuaishou, conducted share buybacks on October 14, 2025, with Xiaomi leading in terms of buyback amount and quantity [1]. Group 1: Buyback Details - Xiaomi Group-W (01810) repurchased 4 million shares for a total of 195 million, with a year-to-date total of 10.5954 million shares, representing 0.040% of its total share capital [2]. - Kuaishou-W (01024) repurchased 1.3146 million shares for 98.4067 million, with a year-to-date total of 3.4516 million shares, representing 0.081% of its total share capital [2]. - Shoucheng Holdings (00697) repurchased 16.05 million shares for 36.3578 million, with a year-to-date total of 90.146 million shares, representing 1.237% of its total share capital [2]. Group 2: Other Notable Buybacks - Vitasoy International (00345) repurchased 1.3980 million shares for 11.3964 million, with a year-to-date total of 4.25 million shares, representing 0.405% of its total share capital [2]. - IGG (00799) repurchased 150,000 shares for 6.145 million, with a year-to-date total of 17.809 million shares, representing 1.527% of its total share capital [3]. - China Hongqiao (01378) repurchased 300,000 shares for 7.594 million, with a year-to-date total of 154 million shares, representing 1.650% of its total share capital [2].

Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan, indicating confidence in its financial position and future prospects [1] Group 1 - The company will spend HKD 3.8695 million to repurchase 300,000 shares [1] - The buyback is scheduled for October 14, 2025, reflecting a strategic move to enhance shareholder value [1]

Group 1 - The company, Heptagon Pharmaceuticals-B (02142), announced a share buyback plan [1] - The company will spend HKD 3.8695 million to repurchase 300,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 和鉑醫藥控股有限公司 呈交日期： 2025年10月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02142 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | | 已發行股份（不包 ...

Summary of Key Points Core Viewpoint - The company, HAPO Pharmaceutical-B, has been actively repurchasing its shares, indicating a strategy to support its stock price amidst recent declines [2][3]. Share Buyback Activity - On October 13, the company repurchased 250,000 shares at prices ranging from HKD 13.280 to HKD 13.460, totaling HKD 3.344 million [2]. - The stock closed at HKD 13.350 on the same day, reflecting a decline of 5.45%, with a total trading volume of HKD 225 million [2]. - Since October 9, the company has conducted buybacks for three consecutive days, accumulating a total of 500,000 shares repurchased for HKD 6.944 million, during which the stock price fell by 18.99% [2]. Year-to-Date Buyback Summary - Year-to-date, the company has executed 50 buybacks, totaling 22.093 million shares and an aggregate amount of HKD 14.730 million [3]. - The detailed buyback activities include various dates, share quantities, and price ranges, showcasing a consistent effort to stabilize the stock price [4].

智通财经APP讯，和铂医药-B(02142)发布公告，于2025年10月13日，该公司斥资334.4万港元回购25万 股股份，每股回购价格为13.28-13.46港元。 ...

和铂医药-B(02142)发布公告，于2025年10月13日，该公司斥资334.4万港元回购25万股股份，每股回购 价格为13.28-13.46港元。 ...

Core Viewpoint - Heptagon Pharmaceuticals-B (02142.HK) announced a share buyback of 250,000 shares at a cost of HKD 3.34 million on October 13 [1] Group 1 - The company executed a buyback program, indicating confidence in its stock value [1] - The total expenditure for the buyback was HKD 3.34 million [1] - The number of shares repurchased was 250,000 [1]